X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/14/2846261/0/en/180-Life-Sciences-Regains-Full-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com//news-release/2023/11/28/2787010/0/en/180-Life-Sciences-Announces-Review-of-Strategic-Alternatives.html
https://www.globenewswire.com/news-release/2023/08/14/2725042/0/en/180-Life-Sciences-Corp-Announces-Closing-of-3-Million-Public-Offering.html
https://www.globenewswire.com/news-release/2023/08/10/2722711/0/en/180-Life-Sciences-Corp-Announces-Pricing-of-3-Million-Public-Offering.html
https://www.globenewswire.com/news-release/2023/08/07/2719752/0/en/180-Life-Sciences-Announces-an-Agreement-for-a-Clinical-Pharmacology-Study-Testing-a-New-Formulation-of-CBD-for-Enhanced-Oral-Uptake.html
https://www.globenewswire.com/news-release/2023/08/03/2717975/0/en/180-Life-Sciences-Provides-Update-on-Regulatory-Approval-Process-in-the-UK-and-US-for-Dupuytren-s-Disease-Treatment-Continues-Consultations-with-the-UK-MHRA-and-Initiates-a-Type-C-.html
https://www.globenewswire.com/news-release/2023/07/31/2714846/0/en/180-Life-Sciences-Corp-Announces-the-Filing-of-a-Provisional-Patent-Describing-the-Combination-of-CBD-With-GLP-1-Agonists-to-Suppress-Appetite.html
https://www.globenewswire.com/news-release/2023/04/10/2643969/0/en/180-Life-Sciences-Corp-Announces-Closing-of-3-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html
https://www.globenewswire.com/news-release/2023/04/05/2642067/0/en/180-Life-Sciences-Corp-Announces-3-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html
https://www.globenewswire.com/news-release/2023/02/27/2616112/0/en/180-Life-Sciences-Announces-Presentation-at-the-Gordon-Conference.html
Market Place
Share 
